 GAINESVILLE, Fla.--BUSINESS WIRE--Cyclo Therapeutics, Inc. Nasdaq: CYTH Cyclo Therapeutics or the Company, a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families suffering from diseases, today announced topline data from its Phase 12 clinical trial, which demonstrated promising safety and efficacy results for Trappsol CycloTM in the treatment of Niemann-Pick Disease type C1, a rare, genetic disea 